Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-24.77M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6842.31% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -65.54% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.46 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 52.79M |
| Free Float | 51.52M |
| Market Capitalization | $22.02M |
| Average Volume (Last 20 Days) | 1.19M |
| Beta (Past 60 Months) | 2.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.21% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |